Strontium-89 therapy and imaging with bremsstrahlung in bone metastases.
Strontium-89 therapy and imaging with bremsstrahlung in bone metastases.
复制标题
骨转移中的锶 89 治疗和轫致辐射成像。
DOI：
--
复制
发表时间：
1997
影响因子：
10.6
通讯作者：
K. Kawakami
中科院分区：
文献类型：
--
作者：
M. Uchiyama;H. Narita;M. Makino;H. Sekine;Y. Mori;N. Fukumitsu;K. Kawakami
寻骨放射性药物Sr-89已被用作骨转移引起的骨痛患者的姑息性治疗。作者报告了9例患者（3例前列腺癌，4例乳腺癌，1例甲状腺癌，1例肺癌）因疼痛性骨转移而接受Sr-89氯化物治疗的结果，并利用轫致辐射评估Sr-89成像。采用1.5和2.2 MBq/kg两个剂量水平。7例患者注射后1周行Sr-89显像。所有患者摄取异常，与Tc-99m HMDP成像结果一致。6例患者在3个月时进行评估，3例患者在接近末期时进行评估；78%（9人中有7人）获得了一些好处。2例患者临床反应良好，Tc-99m HMDP影像学改善。
The bone-seeking radiopharmaceutical Sr-89 has been used as a palliative treatment for patients with bone pain caused by bone metastases. The authors report the results of nine patients (three with prostate cancer, four with breast cancer, one with thyroid cancer, and one with lung cancer) who underwent therapy with Sr-89 chloride for painful bone metastases, and evaluate Sr-89 imaging with bremsstrahlung. Two levels of dosage (1.5 and 2.2 MBq/kg) were used. Sr-89 imaging was performed in seven patients 1 week after injection. Abnormal uptake was seen in all and was consistent with the results of Tc-99m HMDP imaging. Six patients were assessed at 3 months and three patients toward the time they were terminal; 78% (seven of nine) derived some benefit. Two patients had a favorable clinical response and showed improvement on Tc-99m HMDP imaging.
钇 90 轫致辐射的平面伽马相机成像和定量。
DOI：
--
发表时间：
1994
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
--
作者：
Shen,S;DeNardo,GL;Yuan,A;DeNardo,DA;DeNardo,SJ
通讯作者：
DeNardo,SJ
钇 90 治疗应用中的轫致辐射剂量。
DOI：
--
发表时间：
1994
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
--
作者：
Stabin,MG;Eckerman,KF;Ryman,JC;Williams,LE
通讯作者：
Williams,LE